Investigation into the Development Status of the Veterinary Drug Industry in 2025 and Future Market Prospects

As a core support for the animal husbandry and pet economy, the veterinary drug industry is accelerating its transformation from traditional production models to innovation-driven approaches. Driven by factors such as the scaling of aquaculture, the rise of the pet economy, and the emphasis on green environmental protection, the industry faces multiple opportunities including demand upgrades, technological innovation, and the restructuring of competitive landscapes. China's veterinary drug market has developed a diversified product system covering biological products, chemical drug preparations, traditional Chinese medicines, and additives. Future growth potential will be unleashed in areas such as novel biological vaccines, green antibiotic alternatives, and pet-specific medications. However, challenges such as insufficient technological innovation capabilities, increasingly stringent regulatory policies, and intensified market competition still require vigilance. This article provides a strategic reference for industry participants by analyzing dimensions including industry background, development status, core challenges, future trends, market prospects, investment recommendations, and risk warnings.

I. Industry Background: Dual Engines of Policy Drive and Demand Upgrade

The evolution of the veterinary drug industry can be divided into three stages: an early extensive development stage focusing on antibiotics and chemical drugs, a mid-term standardized development stage centered on GMP certification and disease prevention and control, and the current intelligent upgrading stage guided by technological innovation and green environmental protection. In recent years, the state has promoted the industry's transition toward standardization and intensification through policies such as the new GMP certification and veterinary drug residue limit standards. Simultaneously, the increasing scale of aquaculture and the rise of the pet economy have provided new growth space for the veterinary drug industry. For example, large-scale aquaculture enterprises' demand for high-end vaccines and diagnostic reagents has increased, while pet owners' growing concern for pet health and welfare has driven the rapid development of the pet veterinary drug market.

At the policy level, the state has established a comprehensive support system for the veterinary drug industry, spanning from technology research and development to market application, through initiatives such as the "14th Five-Year Plan" and key research and development programs. Local governments have further accelerated technology implementation and business model innovation through pilot projects in areas like the transformation and upgrading of animal husbandry and pet healthcare. This dual-driven model of "policy-demand" has given China's veterinary drug industry a first-mover advantage in global competition.

II. Development Status of the Veterinary Drug Industry: From Scale Expansion to Value Deepening

1. Industrial Scale and Structural Optimization

China's veterinary drug industry has formed a dual-driven structure of "economic animal drugs + pet drugs." In the economic animal drug sector, chemical drug preparations and biological products dominate, with sustained growth in demand for high-end products such as vaccines and diagnostic reagents. In the pet drug sector, product categories such as pet vaccines, deworming medications, and dermatological drugs are increasingly diverse, with market penetration gradually rising. At the industrial chain level, the integration of "R&D-production-sales-service" is becoming prominent. Leading companies are building competitive advantages through full industrial chain layouts, while small and medium-sized enterprises are deepening their presence in niche areas through differentiated competition.

2. Technological Architecture Upgrade and Scenario Implementation

At the technological level, new products such as genetically engineered vaccines, mRNA vaccines, and traditional Chinese veterinary medicines are continuously emerging. Intelligent production equipment and digital management systems are enhancing production efficiency. In terms of application, large-scale farms have significantly reduced disease incidence through measures such as optimized vaccine immunization programs and disease monitoring systems. Pet hospitals are improving pet health management through scenarios like remote diagnosis and treatment and smart medication reminders. Additionally, the development of green and environmentally friendly veterinary drugs is accelerating to meet consumer demands for food safety and environmental protection.

3. Ecological Competition and Model Innovation

Leading companies are extending their reach to upstream and downstream sectors through mergers and acquisitions, self-construction, or strategic partnerships, building ecosystem models across the entire chain. For example, biological product companies are collaborating with aquaculture groups to provide comprehensive disease prevention and control solutions. Pet drug companies are enhancing market coverage through integrated online and offline channel strategies. This ecological competition model accelerates technology diffusion and scenario replication but also intensifies survival pressure for small and medium-sized enterprises.

III. Core Challenges: The Triangular Dilemma of Technology, Policy, and Market

1. Technological Bottlenecks and Insufficient Innovation

The veterinary drug industry is technology-intensive, yet it currently faces bottlenecks that hinder industrial upgrading. For instance, the development cycle for new vaccines is long and requires substantial investment, while the standardization and modernization of traditional Chinese veterinary medicines progress slowly. Additionally, veterinary drug production processes and quality control technologies need improvement. Some companies still rely on traditional production methods, making it difficult to meet market demands for efficient, low-residue, and environmentally friendly veterinary drugs.

2. Policy Regulation and Compliance Pressure

Government regulations on the veterinary drug industry are becoming increasingly stringent, with a series of policies, regulations, and standards being introduced. For example, veterinary drug GMP certification and veterinary drug residue limit standards impose higher requirements on corporate production and operations, increasing compliance costs and operational risks. Moreover, strengthened environmental policies have led to stricter supervision of wastewater and exhaust gas emissions during veterinary drug production, requiring companies to invest more resources in environmental upgrades.

3. Market Competition and Price Wars

The veterinary drug market is highly competitive, with severe product homogenization leading to price wars as a prominent manifestation of internal competition. Tender catalogs for vaccines and drugs disclosed by some listed pig enterprises show significant price drops, compressing profit margins for companies. At the same time, competition in market channels is intense. Companies are increasing investments in online channels, building e-commerce platforms, or partnering with e-commerce players in hopes of boosting sales through broader channel coverage. However, this competitive approach also exacerbates internal industry consumption, which is detrimental to long-term healthy development.